SecBot SecBot
8-K ·Filed Jun 1, 2026

ONCY

ONCOLYTICS BIOTECH INC
NEUTRAL
Impact 3/10
Horizonmonths Processed5mo ago SEC0001129928-26-000037
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor for full preclinical data presentation in late 2026, which could serve as a catalyst if results are compelling. Near-term stock movement likely muted given early stage.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.06
T+0 close · Jun 1, 2026 · via day close
Latest settled
−18.74%
T+60 · $0.8614
Vs SPY
−19.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $1.06entry
  2. T+1 · 6mo ago −12.26%α −12.41% · $0.9300
  3. T+5 · 5mo ago −20.75%α −18.00% · $0.8400
  4. T+20 · 5mo ago −10.39%α −9.09% · $0.9499
  5. T+60 · 3mo ago −18.74%α −19.97% · $0.8614
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncologics Biotech announced initial preclinical data showing pelareorep combined with RAS inhibitors demonstrates greater anti-tumor activity in solid tumor models. The company plans additional studies in pancreatic and colorectal cancer, with full data expected in late 2026. This early-stage preclinical news provides a minor catalyst but no financial impact.

Key Facts

  • Pelareorep + RAS inhibitor modalities showed greater anti-tumor activity than individual approaches in a solid tumor model
  • Additional studies planned in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models
  • Full results from initial preclinical studies expected in fall or winter 2026
  • No financial terms or material agreements disclosed

Financial Impact

No financial figures provided; preclinical stage, no immediate revenue or expense impact

Risk Factors

  • Preclinical results may not translate to clinical efficacy
  • No financial data or guidance provided
  • Small-cap biotech volatility with low liquidity

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001129928-26-000037
Document: 0001129928-26-000037-index-headers.html0001129928-26-000037
Document: 0001129928-26-000037-index.html0001129928-26-000037
Document: 0001129928-26-000037.txt0001129928-26-000037

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026